From seabed to bedside: a review on promising marine anticancer compounds
MetadataShow full item record
The marine environment represents an outstanding source of antitumoral compounds and, at the same time, remains highly unexplored. Organisms living in the sea synthesize a wide variety of chemicals used as defense mechanisms. Interestingly, a large number of these compounds exert excellent antitumoral properties and have been developed as promising anticancer drugs that have later been approved or are currently under validation in clinical trials. However, due to the high need for these compounds, new methodologies ensuring its sustainable supply are required. Also, optimization of marine bioactives is an important step for their success in the clinical setting. Such optimization involves chemical modifications to improve their half-life in circulation, potency and tumor selectivity. In this review, we outline the most promising marine bioactives that have been investigated in cancer models and/or tested in patients as anticancer agents. Moreover, we describe the current state of development of anticancer marine compounds and discuss their therapeutic limitations as well as different strategies used to overcome these limitations. The search for new marine antitumoral agents together with novel identification and chemical engineering approaches open the door for novel, more specific and efficient therapeutic agents for cancer treatment
Is part ofBiomolecules, 2020, vol. 10, núm. 2
European research projects
The following license files are associated with this item:
Showing items related by title, author, creator and subject.
Sorolla Bardají, Maria Alba; Parisi Capdevila, Eva; Sorolla Bardají, Anabel (MDPI, 2020)Radiotherapy is one of the cornerstone treatments for endometrial cancer and has successfully diminished the risk of local recurrences after surgery. However, a considerable percentage of patients suffers tumor relapse due ...
Expression of somatostatin receptors in human melanoma cell lines: effect of two different somatostatin analogues, octreotide and SOM230, on cell proliferation Martínez Alonso, Montserrat; Llecha Cano, Núria; Mayorga Mayorga, Maritza Elfride; Sorolla Bardají, Anabel; Dolcet Roca, Xavier; Sanmartín Novell, Verònica; Abal Diaz, Leandro; Casanova i Seuma, Josep M. (Josep Manel); Baradad Brusau, Manuel; Yeramian Hakim, Andree; Egido Garcia, Ramon Maria; Puig, Susana; Vilella, Ramón; Matias-Guiu, Xavier; Martí Laborda, Rosa Ma. (Field House Publishing, 2009)Somatostatin analogues (SAs) are potential anticancer agents. This study was designed to investigate the expression of somatostatin receptors (SSTRs) in melanoma cells and the effect of two SAs on cell proliferation and ...
Antioxidants impair anti-tumoral effects of Vorinostat, but not anti-neoplastic effects of Vorinostat and caspase-8 downregulation Bergadà Bertran, Laura; Yeramian Hakim, Andree; Sorolla Bardají, Anabel; Matias-Guiu, Xavier; Dolcet Roca, Xavier (Public Library of Science, 2014)We have recently demonstrated that histone deacetylase inhibitor, Vorinostat, applied as a single therapy or in combination with caspase-8 downregulation exhibits high anti-tumoral activity on endometrial carcinoma cell ...